AstraZeneca’s China woes recede as focus shifts to upcoming readouts

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition

France pauses chikungunya vaccinations in the elderly after patient death

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination